Intracoronary abciximab reduces death and major adverse cardiovascular events in acute coronary syndromes: A meta-analysis of clinical trials
Abstract: Background: Successful reperfusion of epicardial coronary arteries does not necessarily result in actual myocardial perfusion. Local intracoronary (IC) delivery of GP IIb/IIIa inhibitors (GPI) has been proposed to achieve further clinical efficacy when compared to standard intravenous (IV) administration. However clinical trials have shown conflicting results. The aim of the present study was to compare IC with IV abciximab administration on mortality and MACEs in patients with ACS undergoing PCI.Methods: We performed a meta-analysis of all available clinical trials comparing intracoronary versus intravenous abci...
Source: International Journal of Cardiology - September 30, 2013 Category: Cardiology Authors: Salvatore De Rosa, Gianluca Caiazzo, Daniele Torella, Ciro Indolfi Tags: Original Articles Source Type: research
Thromboaspiration and IIb/IIIa therapy in STEMI: Abciximab redux?
(Source: Catheterization and Cardiovascular Interventions)
Source: Catheterization and Cardiovascular Interventions - September 23, 2013 Category: Cardiovascular & Thoracic Surgery Authors: William B. Hillegass, Brigitta C. Brott Tags: Coronary Artery Disease Source Type: research
Relation Between White Blood Cell Count and Final Infarct Size in Patients With ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (from the INFUSE AMI Trial)
Although it has been shown that elevated white blood cell count (WBCc) on presentation is associated with an increased risk of cardiac mortality in patients with ST-segment elevation myocardial infarction (STEMI), the responsible mechanisms are unknown. We therefore sought to investigate whether elevated WBCc is associated with increased infarct size measured with cardiac magnetic resonance imaging 30 days after primary percutaneous coronary intervention in the Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction trial. INFUSE AMI randomized patients with STEMI and prox...
Source: The American Journal of Cardiology - September 23, 2013 Category: Cardiology Authors: Tullio Palmerini, Sorin J. Brener, Philippe Genereux, Akiko Maehara, Diego Della Riva, Andrea Mariani, Bernhard Witzenbichler, Jacek Godlewski, Helen Parise, Jan-Henk E. Dambrink, Andrzej Ochala, Martin Fahy, Ke Xu, C. Michael Gibson, Gregg W. Stone Tags: Coronary Artery Disease Source Type: research
Intracoronary Versus Intravenous Abciximab Bolus in Patients With ST-Segment Elevation Myocardial Infarction 1-Year Results of the Randomized AIDA STEMI Trial
In patients with ST-segment elevation myocardial infarction (STEMI), direct intracoronary as compared with standard intravenous bolus administration of the glycoprotein IIb/IIIa receptor antagonist abciximab acutely causes higher local drug concentrations, greater glycoprotein IIb/IIIa receptor occupancy, and enhanced inhibition of platelet aggregation at the site of thrombus and downstream within the coronary capillary bed (1). These effects might exert a protective effect on the myocardial microcirculation at the time of reperfusion. (Source: Journal of the American College of Cardiology: Cardiovascular Interventions)
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - September 16, 2013 Category: Cardiology Source Type: research
Incidence and prognostic value of bleeding after percutaneous coronary intervention in patients older than 75 years of age
Conclusions Post‐PCI bleeding is an important prognostic factor in patients >75 years of age. The risk for bleeding in this age category is increased in women and patients with impaired renal function. Bleeding risk is reduced by bivalirudin. © 2013 Wiley Periodicals, Inc. (Source: Catheterization and Cardiovascular Interventions)
Source: Catheterization and Cardiovascular Interventions - September 13, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Gjin Ndrepepa, Franz‐Josef Neumann, Stefanie Schulz, Massimiliano Fusaro, Salvatore Cassese, Robert A. Byrne, Gert Richardt, Karl‐Ludwig Laugwitz, Adnan Kastrati Tags: Original Study Source Type: research
Outcomes in diabetic patients undergoing primary percutaneous coronary intervention for acute anterior myocardial infarction: Results from the INFUSE‐AMI study
Conclusions: Patients with DM presenting with STEMI had a higher baseline risk profile than those without DM. Although reperfusion success and infarct size were similar, diabetic patients experienced more death, reinfarction, stent thrombosis and revascularization than non‐diabetics. © 2013 Wiley Periodicals, Inc. (Source: Catheterization and Cardiovascular Interventions)
Source: Catheterization and Cardiovascular Interventions - September 13, 2013 Category: Cardiovascular & Thoracic Surgery Authors: Elias A. Sanidas, Sorin J. Brener, Akiko Maehara, Philippe Généreux, Bernhard Witzenbichler, Magdi El‐Omar, Martin Fahy, Roxana Mehran, C. Michael Gibson, Gregg W. Stone Tags: Original Study Source Type: research
Comparison of bivalirudin with heparin versus abciximab with heparin for primary percutaneous coronary intervention in “Real World” practice
Conclusion: In this “real-world” observational study, there was no significant difference in the clinical outcome of PPCI for patients who had abciximab or bivalirudin after initial pre-treatment with UFH. (Source: Cardiovascular Revascularization Medicine)
Source: Cardiovascular Revascularization Medicine - August 26, 2013 Category: Cardiology Authors: Refai Showkathali, John R. Davies, Michael Parker, Wasing Taggu, Kare H. Tang, Gerald J. Clesham, Reto A. Gamma, Jeremy W. Sayer, Rajesh K. Aggarwal, Paul A. Kelly Tags: Clinical Source Type: research
Endovascular Management of Distal ACA Aneurysms: Single-Institution Clinical Experience in 22 Consecutive Patients and Literature Review [INTERVENTIONAL]
CONCLUSIONS:
The characteristics of the patients and aneurysms treated in our series were comparable to previous reports of endovascular treatment of ACA aneurysms with respect to rupture status. Periprocedural morbidity and mortality rates in our series fared well compared with previous reports, as did our combined rate of complete or near-complete occlusions. Recent advances in endovascular devices and techniques have improved outcomes of distal ACA aneurysms. (Source: American Journal of Neuroradiology)
Source: American Journal of Neuroradiology - August 14, 2013 Category: Radiology Authors: Cavalcanti, D. D., Abla, A. A., Martirosyan, N. L., McDougall, C. G., Spetzler, R. F., Albuquerque, F. C. Tags: INTERVENTIONAL Source Type: research
Intra-Arterial Infusion of a Glycoprotein IIb/IIIa Antagonist for the Treatment of Thromboembolism During Coil Embolization of Intracranial Aneurysm: A Comparison of Abciximab and Tirofiban [INTERVENTIONAL]
CONCLUSIONS:
These results suggest that tirofiban is more effective than abciximab for the immediate resolution of thromboembolisms, with no statistical significance. Both intra-arterial tirofiban and abciximab exhibited similar safety and recanalization rates. (Source: American Journal of Neuroradiology)
Source: American Journal of Neuroradiology - August 14, 2013 Category: Radiology Authors: Jeong, H. W., Jin, S.- C. Tags: INTERVENTIONAL Source Type: research
Current state of clinical translation of cardioprotective agents for acute myocardial infarction.
Abstract
There is continued interest in the concept of limiting myocardial infarct size with adjunctive agents administered along with reperfusion injury; however, there remains considerable controversy in the literature. The purpose of this article is to review the medical literature on clinical trials performed during the past 3 years that have attempted to reduce myocardial infarct size by administration of adjunctive therapies along with reperfusion therapy. A PubMed-driven literature search revealed a host of clinical trials focusing on the following prominent types of therapies: endogenous conditioni...
Source: Circulation Research - August 2, 2013 Category: Cardiology Authors: Kloner RA Tags: Circ Res Source Type: research
Intracoronary Glycoprotein IIb/IIIa Inhibitors Downstream of the Coronary Occlusion: The “Highway” to Periphery
We read with interest the study of Eitel et al. (1) about the AIDA STEMI (Abciximab i.v. Versus i.c. in ST-Elevation Myocardial Infarction) trial, regarding infarct size. The study shows an interesting result: Microvascular Obstruction (MO) and infarct size did not significantly differ between intravenous versus intracoronary administration of abciximab. (Source: Journal of the American College of Cardiology: Cardiovascular Imaging)
Source: Journal of the American College of Cardiology: Cardiovascular Imaging - July 22, 2013 Category: Radiology Source Type: research
Reply
We thank Drs. Iancu and Ober for their interest in our work (1). We agree that timing of glycoprotein IIb/IIIa inhibitor administration is an important factor. A recent meta-analysis comparing intravenous versus intracoronary abciximab application found a trend toward a greater efficacy with intracoronary abciximab with an ischemic time (Source: Journal of the American College of Cardiology: Cardiovascular Imaging)
Source: Journal of the American College of Cardiology: Cardiovascular Imaging - July 22, 2013 Category: Radiology Source Type: research
Intracoronary Versus Intravenous Abciximab Bolus in Patients With ST-Segment Elevation Myocardial Infarction: 1-Year Results of the Randomized AIDA STEMI Trial
In patients with ST-segment elevation myocardial infarction (STEMI), direct intracoronary as compared with standard intravenous bolus administration of the glycoprotein IIb/IIIa receptor antagonist abciximab acutely causes higher local drug concentrations, greater glycoprotein IIb/IIIa receptor occupancy, and enhanced inhibition of platelet aggregation at the site of thrombus and downstream within the coronary capillary bed . These effects might exert a protective effect on the myocardial microcirculation at the time of reperfusion. (Source: Journal of the American College of Cardiology)
Source: Journal of the American College of Cardiology - July 12, 2013 Category: Cardiology Authors: Steffen Desch, Jochen Wöhrle, Rainer Hambrecht, Harald Rittger, Ralf Birkemeyer, Bernward Lauer, Petra Neuhaus, Oana Brosteanu, Peter Sick, Matthias Pauschinger, Sebastian Kerber, Klaus Kleinertz, Suzanne de Waha, Ingo Eitel, Gerhard Schuler, Holger Thie Tags: Research Correspondence Source Type: research
Approach to the Diagnosis and Management of Drug-Induced Immune Thrombocytopenia
Abstract: Drug-induced immune thrombocytopenia (DITP) is a challenging clinical problem that is under-recognized, difficult to diagnose and associated with severe bleeding complications. DITP may be caused by classic drug-dependent platelet antibodies (eg, quinine); haptens (eg, penicillin); fiban-dependent antibodies (eg, tirofiban); monoclonal antibodies (eg, abciximab); autoantibody formation (eg, gold); and immune complex formation (eg, heparin). A thorough clinical history is essential in establishing the diagnosis of DITP and should include exposures to prescription medications, herbal preparations and even certain f...
Source: Transfusion Medicine Reviews - July 10, 2013 Category: Hematology Authors: Donald M. Arnold, Ishac Nazi, Theodore E. Warkentin, James W. Smith, Lisa J. Toltl, James N. George, John G. Kelton Tags: Original Articles Source Type: research
